Correlative clinical trial results: CD4⁺ T cells in the pretherapy TME correlate with an increase in NK-cell CD16 and CD25 expression after RTX-containing therapy. (A) Clinical trial schema: patients (n = 10) with indolent B-cell lymphoma were treated with RTX and bendamustine based on clinical indications. FNAs from involved nodes were obtained before and 7 to 14 days after the first course of treatment. Pretherapy frequency of CD3⁺, CD4⁺, and CD8⁺ cells in the TME was correlated with pretherapy to posttherapy changes in expression intensity by NK cells of CD16 (B-D) and CD25 (E-G) as well as CD19 cell frequency (H-J).